Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo.

[1]  S. Welle,et al.  Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. , 2006, American journal of physiology. Endocrinology and metabolism.

[2]  J. Link,et al.  Progress towards glucagon receptor antagonist therapy for Type 2 diabetes , 2005 .

[3]  V. Ding,et al.  Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[4]  G. Dailey.  Insulin secretagogues: Who, what, when, and how? , 2005, Current diabetes reports.

[5]  J. Ristic,et al.  Canine diabetes mellitus: can old dogs teach us new tricks? , 2005, Diabetologia.

[6]  R. Kawamori,et al.  FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. , 2005, Metabolism: clinical and experimental.

[7]  L. Öhman,et al.  Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes , 2005, Journal of Pharmacology and Experimental Therapeutics.

[8]  M. Michael,et al.  Glucagon as a target for the treatment of Type 2 diabetes , 2005, Expert opinion on therapeutic targets.

[9]  D. Edgerton,et al.  Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. , 2005, Diabetes.

[10]  V. Ding,et al.  Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor. , 2005, Bioorganic & medicinal chemistry letters.

[11]  D. Moller,et al.  A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. , 2004, Diabetes.

[12]  P. Marin,et al.  GPCR-interacting proteins (GIPs): nature and functions. , 2004, Biochemical Society transactions.

[13]  T. Pederson,et al.  Cloning and characterization of the glucagon receptor from cynomologous monkey , 2004, Peptides.

[14]  Jyoti R. Patel,et al.  Biaryl amide glucagon receptor antagonists. , 2004, Bioorganic & medicinal chemistry letters.

[15]  D. Edgerton,et al.  Effects of hyperglycemia on hepatic gluconeogenic flux during glycogen phosphorylase inhibition in the conscious dog. , 2004, American journal of physiology. Endocrinology and metabolism.

[16]  R. Vulliet,et al.  Evaluation of the Oral Antihyperglycemic Drug Metformin in Normal and Diabetic Cats , 2004 .

[17]  Philippe Marin,et al.  The ‘magic tail’ of G protein‐coupled receptors: an anchorage for functional protein networks , 2003, FEBS letters.

[18]  Bei B. Zhang,et al.  Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.

[19]  A. Kuki,et al.  Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. , 2002, Journal of medicinal chemistry.

[20]  S. Djurić,et al.  Glucagon receptor antagonists for the treatment of type II diabetes: current prospects. , 2002, Current opinion in investigational drugs.

[21]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[22]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[23]  J. Ristic,et al.  Research into canine diabetes mellitus. , 2003, The Veterinary record.

[24]  K. Petersen,et al.  Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans , 2001, Diabetologia.

[25]  C. Chu,et al.  The acute effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition of glycogenolysis. , 2000, Metabolism: clinical and experimental.

[26]  Carolyn B Levy,et al.  Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. , 2000, Diabetes.

[27]  R. Rizza,et al.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.

[28]  M. Maccoss,et al.  Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor* , 1999, The Journal of Biological Chemistry.

[29]  M. Maccoss,et al.  Potent, orally absorbed glucagon receptor antagonists. , 1999, Bioorganic & medicinal chemistry letters.

[30]  A. Strosberg,et al.  Genomic cloning and species-specific properties of the recombinant canine beta3-adrenoceptor. , 1998, European journal of pharmacology.

[31]  D. Edgerton,et al.  The direct and indirect effects of insulin on hepatic glucose production in vivo , 1998, Diabetologia.

[32]  M. Graziano,et al.  Alterations in Receptor Activation and Divalent Cation Activation of Agonist Binding by Deletion of Intracellular Domains of the Glucagon Receptor* , 1997, The Journal of Biological Chemistry.

[33]  M. Davidson,et al.  An overview of metformin in the treatment of type 2 diabetes mellitus. , 1997, The American journal of medicine.

[34]  R. Burcelin,et al.  Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. , 1996, Diabetes & metabolism.

[35]  R. Burcelin,et al.  Cloning and sequence analysis of the murine glucagon receptor-encoding gene. , 1995, Gene.

[36]  F. Grant,et al.  The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. , 1994, Gene.

[37]  C. Strader,et al.  Cloning and expression of a human glucagon receptor. , 1994, Biochemical and biophysical research communications.

[38]  F J Grant,et al.  Expression cloning and signaling properties of the rat glucagon receptor. , 1993, Science.

[39]  P. Grasso,et al.  The Use of the Dog in Toxicity Tests on Pharmaceutical Compounds , 1993, Human & experimental toxicology.

[40]  A. Consoli.  Role of Liver in Pathophysiology of NIDDM , 1992, Diabetes Care.

[41]  A. Cherrington,et al.  Role of glucagon in countering hypoglycemia induced by insulin infusion in dogs. , 1991, The American journal of physiology.

[42]  R. B. Merrifield,et al.  Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist , 1989, Peptides.

[43]  D. Wasserman,et al.  Glucagon is a primary controller of hepatic glycogenolysis and gluconeogenesis during muscular work. , 1989, The American journal of physiology.

[44]  N. Saitou,et al.  The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.

[45]  R. B. Merrifield,et al.  Synthetic peptide antagonists of glucagon. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Golay,et al.  Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. , 1987, The Journal of clinical endocrinology and metabolism.

[47]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[48]  V. Hruby,et al.  Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. , 1982, Science.

[49]  G WhittakerP,et al.  共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値 , 1980 .

[50]  R. Unger,et al.  Role of glucagon in the pathogenesis of diabetes: the status of the controversy. , 1978, Metabolism: clinical and experimental.

[51]  A. Cherrington,et al.  Control of hepatic glucose output by glucagon and insulin in the intact dog. , 1978, Biochemical Society Symposium.

[52]  L. Orci,et al.  THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.

[53]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.